ANAHEIM, CA, Feb. 25, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioCorRx Inc. (OTCQB: BICX) (“Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today the addition of two new independent directors, Louis Lucido and Luisa Ingargiola, to the Company’s Board of Directors.

“We are delighted to welcome Lou and Luisa as new independent directors. Luisa has served as both a CFO and board member of multiple public companies, and has been instrumental in assisting several of these companies in the uplisting process to a senior national exchange. Lou brings extensive business acumen, having founded and helped run a multi-billion dollar asset management firm. As we continue executing on our growth strategy and plan for a Nasdaq listing, these new directors bring a wide range of relevant experience. We believe that the breadth, depth and diversity of their experience in both corporate finance and capital markets will strengthen BioCorRx on many levels,” said Brady Granier, CEO, President and Director of BioCorRx. “They have impressive track records and we look forward to working with them as we believe they will have a meaningful impact on BioCorRx’s future growth.”

Louis Lucido

Louis Lucido was formerly the Senior Advisor and Chief Operating Officer of DoubleLine Group, LP, a large investment firm with over $100 billion in assets under management. He recently retired in December 2018 and was one of the five founding partners. He was previously at TCW, where he served as a Group Managing Director. Prior to joining TCW in 2001, Mr. Lucido was the Chief Investment Officer for Delphi Financial Group (DFG) and was on several subsidiary boards. Before DFG, he was the Chief Operating Officer and Secretary for Hyperion Capital Management and was also a member of the Resolution Trust Advisory Committee. Since February 2013, he has served as a member of the Board of Directors of CASA of Los Angeles and is the current Chairman. Additionally, he was elected in 2013 and currently serves on the Boards of Junior Achievement, Southern California ,826LA and the Lupus Research Alliance (formerly the Alliance for Lupus Research). Mr. Lucido received his MBA in Management and Finance from New York University, and was a member of the Dean’s Advisory Board of the N.Y.U. Stern School of Business.

Luisa Ingargiola

Luisa Ingargiola presently serves as Chief Financial Officer of Avalon GloboCare, a leading global developer of cell-based technologies and therapeutics, where she helped navigate its Nasdaq uplisting in 2018. Luisa is a Board Director and Audit Chair of Electra Meccanica, a Nasdaq-listed company designing and manufacturing electric vehicles; she also serves on the board of Globe Photos, a leader in licensed sports photographic prints and iconic pop culture imagery; and she serves as director of Operation Transition Corporation, a strategic consulting and advisory firm that places ex-military special operations forces into corporate careers. Luisa holds a Bachelor of Science in Finance from Boston University, and an MBA in Health from the University of South Florida.

About BioCorRx

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids, and can prevent opioid overdose following relapse. The second component of the program developed by BioCorRx Inc. is a Cognitive Behavioral Therapy (CBT) program tailored specifically for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also conducts R&D under its controlled subsidiary, BioCorRx Pharmaceuticals. For more information on BICX and product pipeline, visit www.BioCorRx.com. 

Twitter: @BioCorRxInc

LinkedIn: https://www.linkedin.com/company/biocorrx-inc/  

Facebook: @BioCorRx

Instagram: @biocorrx_inc

Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

BioCorRx Inc.
investors@BioCorRx.com
(714) 462-4880

Investor Relations Contact:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com

Media Relations Contact:
Kyle Porter
CMW Media
kyle@cmwmedia.com
(858) 264-6600

Released February 25, 2019